Preserved pulmonary vasodilative properties of aerosolized brain natriuretic peptide

Pulmonary Pharmacology and Therapeutics

Volumn 22, Issue 6, 2009, Pages 548-553

  Leuchte, Hanno H ^a   Michalek, Jens ^a   Soenmez, Oezcan ^a   Meis, Tobias ^a   Haziraj, Shani ^a   Cavalli, Vera ^b   Bevec, Dorian ^b   Behr, Jürgen ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b mondoBiotech   (Switzerland)

Author keywords

Isolated lung; Natriuretic peptides; Pulmonary hypertension

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; ENDOTHELIN 1; PLACEBO;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; EXPERIMENTAL RABBIT; FEMALE; LUNG ARTERY PRESSURE; LUNG VASOCONSTRICTION; MALE; NONHUMAN; PRIORITY JOURNAL; VASODILATATION;

15-HYDROXY-11 ALPHA,9 ALPHA-(EPOXYMETHANO)PROSTA-5,13-DIENOIC ACID; AEROSOLS; ANIMALS; BLOOD PRESSURE; BUFFERS; CYCLIC GMP; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; NATRIURETIC PEPTIDE, BRAIN; PULMONARY CIRCULATION; RABBITS; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS; VASODILATION;

EID: 71249143887     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2009.07.002     Document Type: Article

References (31)

1. Gomberg-Maitland M., and Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 31 (2008) 891-901
2. Voswinckel R., Enke B., Reichenberger F., Kohstall M., Kreckel A., Krick S., et al. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies. J Am Coll Cardiol 48 (2006) 1672-1681
3. Dupuis J., and Hoeper M.M. Endothelin receptor antagonists in pulmonary arterial hypertension. Eur Respir J 31 (2008) 407-415
4. Leuchte H.H., Meis T., El-Nounou M., Michalek J., and Behr J. Inhalation of endothelin receptor blockers in pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 294 (2008) L772-L777
5. Petkov V., Mosgoeller W., Ziesche R., Raderer M., Stiebellehner L., Vonbank K., et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 111 (2003) 1339-1346
6. Leuchte H.H., Baezner C., Baumgartner R.A., Bevec D., Bacher G., Neurohr C., et al. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J 32 (2008) 1289-1294
7. Koller K.J., and Goeddel D.V. Molecular biology of the natriuretic peptides and their receptors. Circulation 86 (1992) 1081-1088
8. Hamad A.M., Clayton A., Islam B., and Knox A.J. Guanylyl cyclases, nitric oxide, natriuretic peptides, and airway smooth muscle function. Am J Physiol Lung Cell Mol Physiol 285 (2003) L973-L983
9. Weinberger B., Heck D.E., Laskin D.L., and Laskin J.D. Nitric oxide in the lung: therapeutic and cellular mechanisms of action. Pharmacol Therapeut 84 (1999) 401-411
10. Ghofrani H.A., Pepke-Zaba J., Barbera J.A., Channick R., Keogh A.M., Gomez-Sanchez M.A., et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) S68-S72
11. Amrita A., MacAllister J., and Hobbs J. Vascular actions of natriuretic peptides. Basic Res Cardiol 99 (2004) 83-89
12. Zhao L., Hughes J.M., and Winter R.J. Effects of natriuretic peptides and neutral endopeptidase 24.11 inhibition in isolated perfused rat lung. Am Rev Respir Dis (1992) 1198-1201
13. Cargill R.I., and Lipworth B.J. Acute effects of ANP and BNP on hypoxic pulmonary vasoconstriction in humans. Br J Clin Pharmacol 40 (1995) 585-590
14. Cargill R.I., and Lipworth B.J. Atrial natriuretic peptide and brain natriuretic peptide in cor pulmonale. Hemodynamic and endocrine effects. Chest 110 (1996) 1220-1225
15. Arjona A.A., Hsu C.A., Wrenn D.S., and Hill N.S. Effects of natriuretic peptides on vascular smooth-muscle cells derived from different vascular beds. Gen Pharmacol Vasc Syst 28 (1997) 387-392
16. Klinger J.R., Warburton R.R., Pietras L., and Hill N.S. Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats. J Appl Physiol 84 (1998) 1646-1652
17. Schermuly R.T., Roehl A., Weissmann N., Ghofrani H.A., Schudt C., Tenor H., et al. Subthreshold doses of specific phosphodiesterase type 3 and 4 inhibitors enhance the pulmonary vasodilatory response to nebulized prostacyclin with improvement in gas exchange. J Pharmacol Exp Ther 292 (2000) 512-520
18. Schmehl T., Gebhart J., Schutte H., Scharmann A., and Seeger W. On-line laser-photometric monitoring of aerosol deposition in ventilated rabbit lungs. J Appl Physiol 80 (1996) 351-356
19. Walmrath D., Schermuly R., Pilch J., Grimminger F., and Seeger W. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension. Eur Respir J 10 (1997) 1084-1092
20. Kleen M.M., Habler O.M., Hofstetter C., Mueller M.M., and Zwissler B.M. Efficacy of inhaled prostanoids in experimental pulmonary hypertension. Crit Care Med (1998) 1103-1109
21. Zhao L., Mason N.A., Morrell N.W., Kojonazarov B., Sadykov A., Maripov A., et al. Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 104 (2001) 424-428
22. Zhao L., Long L., Morrell N.W., and Wilkins M.R. NPR-aûdeficient mice show increased susceptibility to hypoxia-induced pulmonary hypertension. Circulation 99 (1999) 605-607
23. Hussain M.B., MacAllister R.J., and Hobbs A.J. Reciprocal regulation of cGMP-mediated vasorelaxation by soluble and particulate guanylate cyclases. Am J Physiol Heart Circ Physiol 280 (2001) H1151-H1159
24. Olschewski H., Rose F., Grunig E., Ghofrani H.A., Walmrath D., Schulz R., et al. Cellular pathophysiology and therapy of pulmonary hypertension. J Lab Clin Med 138 (2001) 367-377
25. Akerman M.J., Yaegashi M., Khiangte Z., Murugan A.T., Abe O., and Marmur J.D. Bronchodilator effect of infused B-type natriuretic peptide in asthma*. Chest 130 (2006) 66-72
26. Schermuly R.T., Weissmann N., Enke B., Ghofrani H.A., Forssmann W.G., Grimminger F., et al. Urodilatin, a natriuretic peptide stimulating particulate guanylate cyclase, and the phosphodiesterase 5 inhibitor dipyridamole attenuate experimental pulmonary hypertension: synergism upon coapplication. Am J Respir Cell Mol Biol 25 (2001) 219-225
27. Klinger J.R., Thaker S., Houtchens J., Preston I.R., Hill N.S., and Farber H.W. Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 129 (2006) 417-425
28. Schermuly R.T., Kreisselmeier K.P., Ghofrani H.A., Samidurai A., Pullamsetti S., Weissmann N., et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 94 (2004) 1101-1108
29. Schermuly R.T., Ghofrani H.A., Enke B., Weissmann N., Grimminger F., Seeger W., et al. Low-dose systemic phosphodiesterase inhibitors amplify the pulmonary vasodilatory response to inhaled prostacyclin in experimental pulmonary hypertension. Am J Respir Crit Care Med 160 (1999) 1500-1506
30. Schermuly R.T., Leuchte H., Ghofrani H.A., Weissmann N., Rose F., Kohstall M.G., et al. Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J 22 (2003) 342-347
31. Ghofrani H.A., Rose F., Schermuly R.T., Olschewski H., Wiedemann R., Kreckel A., et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 42 (2003) 158-164